生物制剂治疗未减少克罗恩病合并短肠综合征患者的手术
该研究基于美国全国住院患者样本中2,989,185例克罗恩病住院患者,比较生物制剂普及前(1993-1997年)与普及后(1998-2014年)小肠切除和医疗资源利用趋势。结果显示生物制剂时代整体切除比例显著下降,但合并短肠综合征与肠衰竭(SBS-IF)患者的切除比例无显著变化,且SBS-IF住院率上升、住院时间更长、总费用更高。
要点
- 生物制剂普及后克罗恩病整体小肠切除比例显著下降,但合并SBS-IF患者无显著变化。
- SBS-IF住院率从1998年16.5/1000住院升至2014年19.5/1000住院(P趋势<.01)。
- SBS-IF住院与更长住院时间和更高总费用相关(P<.01)。
核心结论
- 在美国人群中,使用生物制剂治疗克罗恩病降低了接受切除的患者比例,但在合并SBS-IF的患者中未降低。
- 这些发现表明生物制剂减少了克罗恩病部分而非全部特征。
- 需要研究识别SBS-IF风险患者、预防和治疗该并发症并寻找新治疗方法。
研究设计与样本
- 基于美国全国住院患者样本的住院趋势分析,纳入2,989,185例克罗恩病住院患者。
- 比较生物制剂治疗前时期(1993-1997年)与生物制剂治疗广泛使用后时期(1998-2014年)。
- 采用泊松回归和线性回归分析小肠切除与医疗资源利用趋势。
- 多变量模型校正年龄、性别、Charlson-Deyo合并症指数、支付来源、医院规模、地区及教学状态。
主要发现
- 生物制剂治疗前时期切除比例从1993年121.8/1000住院至1997年110.1/1000住院,无显著变化(P趋势=.14)。
- 生物制剂治疗开始后切除比例从1998年99.0/1000住院降至2014年64.6/1000住院,显著下降(P趋势<.01)。
- 合并SBS-IF患者中,生物制剂治疗前时期切除比例从1993年0.7/1000住院至1997年0.7/1000住院(P趋势=.92),生物制剂治疗后时期从1998年0.6/1000住院至2014年0.7/1000住院(P趋势=.06),均无显著变化。
- SBS-IF患者住院率从1998年16.5/1000住院升至2014年19.5/1000住院(P趋势<.01)。
- SBS-IF住院与更长住院时间(P<.01)和更高总费用(P<.01)相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the effects of biologic agents used to treat Crohn's disease (CD) on its long-term complications, such as short bowel syndrome and intestinal failure (SBS-IF). We evaluated trends in small bowel resections and health care utilization among patients with CD with and without SBS-IF. METHODS: We collected data on the National Inpatient Sample on 2,989,185 patients hospitalized with CD in the United States before the time period in which CD was treated with biologic agents (1993-1997) and after biologic therapy became widespread (1998-2014). We used Poisson and linear regression analyses to evaluate trends for small bowel resections and health care utilization among patients with CD with and without SBS-IF. Multivariable models were adjusted for age, sex, Charlson-Deyo comorbidity index, payer source, hospital size, region, and teaching status. RESULTS: The proportions of patients who underwent resection did not significantly change during the period before biologic therapy (121.8 per 1000 hospitalizations in 1993 to 110.1 per 1000 hospitalizations in 1997; P trend =.14) but decreased significantly during the period after biologic therapy began (99.0 per 1000 hospitalizations in 1998 to 64.6 per 1000 hospitalizations in 2014; P trend < .01). However, among patients with SBS-IF, similar proportions of patients underwent resection during the period before biologic therapy (0.7 per 1000 hospitalizations in 1993 to 0.7 per 1000 hospitalizations in 1997; P trend = .92) and during the period after biologic therapy (0.6 per 1000 hospitalizations in 1998 to 0.7 per 1000 hospitalizations in 2014; P trend = .06). Rates of hospitalization for patients with SBS-IF increased from 16.5 per 1000 hospitalizations in 1998 to 19.5 per 1000 hospitalizations in 2014 (P trend < .01). SBS-IF hospitalizations were associated with longer lengths of stay (P < .01) and greater total charges (P < .01). CONCLUSIONS: In a study of the United States population, we found that the use of biologic agents to treat CD reduced the proportion of patients undergoing resection, but not among patients with SBS-IF. These findings indicate that biologic agents reduce some but not all features of CD. Studies are needed to identify patients at risk for SBS-IF, prevent and treat this complication, and identify new treatments.
引用
- Limketkai BN, Parian AM, Chen PH, et al. Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn's Disease With Short Bowel Syndrome. Clin Gastroenterol Hepatol. 2017. PMID: 28666947. doi:10.1016/j.cgh.2017.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。